LeadStory

Africanews

Novartis reveals new drug to fight malaria resistance, transmission

Africanews · Just In
Africanews
Africanews
Just In

Swiss pharmaceutical giant Novartis has unveiled a next-generation malaria treatment that not only demonstrates a 97% cure rate but also blocks disease transmission, representing a potential breakthrough in combating drug-resistant strains of the deadly parasite.

Breakdown
  • Novartis developed GANLAM, a next-generation malaria treatment, after testing millions of compounds.
  • A study in 12 African countries showed GANLAM effectively combats the malaria parasite and inhibits its spread. 9s
  • GANLAM targets resistant parasites and may help block disease transmission. 24s
  • The study's findings were presented at the American Society of Tropical Medicine and Hygiene conference in Toronto. 35s
  • Malaria kills nearly 600,000 people annually, mostly children in sub-Saharan Africa, according to the World Health Organization. 1m 45s
HealthMedical Research